GS 0976

Drug Profile

GS 0976

Alternative Names: GS-0976; NDI 010976

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator Nimbus Therapeutics
  • Developer Gilead Sciences; Nimbus Therapeutics
  • Class Small molecules
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Non-alcoholic steatohepatitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 01 Sep 2016 Gilead Sciences initiates a phase I pharmacokinetics trial in USA (PO, Capsule) (NCT02891408)
  • 01 Aug 2016 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (PO) (NCT02856555)
  • 25 Jul 2016 Gilead Sciences acquires NDI 010976 from Nimbus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top